MediciNova, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
MNOV Nasdaq 8731 http://www.medicinova.com 6.14 Stock Down -0.05

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MediciNova, Inc.

MediciNova, Upcoming Phase II Data Presentation, Ibudilast Review - Oct 17th, 2017 6:05 am
MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence - Sep 19th, 2017 4:00 am
MediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New York - Sep 18th, 2017 5:00 pm
MediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017 in Paris, France - Aug 30th, 2017 4:00 am
MNOV: MN-166 Shows Activity in Preclinical Brain Cancer Study - Aug 1st, 2017 10:00 am
MNOV: MN-166 Making Progress in Numerous Indications… - Feb 27th, 2017 10:00 am
MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion - Dec 22nd, 2016 9:30 am
MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016 - Dec 15th, 2016 8:32 am